FDA Adds Its Strongest Warning to Iron Drug Injectafer After Patient Advocate's Petition

The FDA announced on September 1, 2026, that it approved a boxed warning, its most serious label alert, for ferric carboxymaltose injection, sold as Injectafer. The warning covers the risk of symptomatic hypophosphatemia, dangerously low blood phosphate, according to the FDA's own drug safety communication.

This isn't the first time the agency has flagged this drug. The FDA added a hypophosphatemia warning in February 2020, strengthened it in May 2023 to recommend phosphate monitoring, and added more risk factors in 2025. None of it worked well enough.

The Data That Forced the Boxed Warning

An FDA assessment in 2026 pulled from the FDA Adverse Event Reporting System, medical literature, and the agency's Sentinel surveillance system. The finding: symptomatic hypophosphatemia is still showing up, and serum phosphate testing rates remain low despite two rounds of prior label warnings, per the FDA.

Cure HHT, a patient advocacy group for hereditary hemorrhagic telangiectasia, reported the FDA's review identified 134 reports and published cases of serious, symptomatic hypophosphatemia tied to the drug between July 1, 2022 and June 30, 2025. Some cases were severe, prolonged, or hard to treat, according to Cure HHT.

That's the mechanism here, not speculation. Doctors weren't testing phosphate levels as often as the 2023 label already told them to. The FDA said as much directly.

A Doctor's Petition Pushed It Over the Line

On August 13, 2026, the FDA granted a citizen petition filed by Scott Olitsky, MD, MBA, the Global Center of Excellence and Outreach Director at Cure HHT. Olitsky argued the existing warnings weren't strong enough given the drug's association with hypophosphatemia and its downstream complications, according to Cure HHT.

People with hereditary hemorrhagic telangiectasia suffer chronic nosebleeds and GI bleeding, driving repeated need for IV iron, sometimes for months or years, Cure HHT said. Repeat dosing raises the stakes, which is exactly what the new label targets. The FDA now recommends phosphate monitoring in at-risk patients and in anyone getting a repeat course within three months of the last one.

One doctor with domain expertise flagged a real problem, backed it with data, and the federal regulatory process worked as designed. No lawsuit, no viral outrage cycle. Just a petition and an evidence review.

What Symptomatic Hypophosphatemia Actually Looks Like

Symptoms include muscle weakness or pain, fatigue, tremors, confusion, seizures, and cardiac arrhythmias, according to the FDA. Left chronic and severe, it can cause osteomalacia, bone softening, and fractures.

MedPage Today reported that FDA adverse event cases included hospitalizations and patients needing phosphate replacement therapy for weeks to months, plus extensive follow-up monitoring. That's not a minor side effect footnote.

The Fair Counterargument

Injectafer isn't a fringe drug. It's approved for iron deficiency anemia in patients age 1 and up who can't tolerate oral iron, for adults with non-dialysis chronic kidney disease, and for heart failure patients to improve exercise capacity, per the FDA. A reasonable concern is that a boxed warning, the label's scariest category, could spook physicians into avoiding an otherwise effective treatment for patients who genuinely need IV iron and have few alternatives.

That's a legitimate tradeoff to weigh. But the label doesn't restrict use or add new contraindications. It adds monitoring requirements. Patients who need the drug can still get it. The ask is simply that doctors check phosphate levels, something the FDA already recommended in 2023 and says didn't happen enough.

A Separate Recall, Different Drug

Separately, Fresenius Kabi recalled one lot of Tyenne (tocilizumab-aazg), an arthritis injection, in August 2026 after finding glass particles in vials, the Epoch Times reported. That recall, tied to lot number 16UI07 and shipped between March 3 and 25, is unrelated to the Injectafer warning. It's a different drug, a different manufacturer, and a different problem: physical contamination rather than a metabolic side effect. Fresenius Kabi said glass particles can cause blood vessel blockage, clotting, and organ damage, and asked providers to stop using the affected lot immediately.

The open question on Injectafer is whether a boxed warning finally changes prescriber behavior where two prior label updates didn't. The FDA's own data says testing rates stayed low after the 2020 and 2023 changes. Patients on repeat IV iron courses have a concrete next step now: ask your provider whether your phosphate level has been checked, especially if it's been less than three months since your last infusion.